Paper28601423
Crohn Disease: Epidemiology, Diagnosis, and Management.
Feuerstein JD and 1 other. Mayo Clin Proc, 2017. Cited by 386 papers, by iCite.
Cite this record
ConductScience Library. Crohn Disease: Epidemiology, Diagnosis, and Management. Papers, record 28601423. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28601423
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Crohn Disease | Major topic |
| Disease Management | Major topic |
| Abdominal Pain | |
| Antibodies, Monoclonal | |
| Diarrhea | |
| Endoscopy | |
| Humans | |
| Recurrence | |
| Risk Factors |
Source PubMed
Cited by300
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 386 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42791370 | Single-cell analysis of chromatin accessibility in the human intestine identifies regulatory programs and clarifies genetic associations in Crohn's disease. | Nat Genet | 2026 | https://conductscience.org/library/papers/42791370 | PubMed |
| 42765439 | Mesenchymal Stem Cells Alleviate Crohn's Disease by Regulating CBS-Mediated Ferroptosis. | Immun Inflamm Dis | 2026 | https://conductscience.org/library/papers/42765439 | PubMed |
| 42657205 | Advancing Equity and Patient Partnership in Clinical Trials for Inflammatory Bowel Disease: A Model for Inclusive Trial Design. | Clin Exp Gastroenterol | 2026 | https://conductscience.org/library/papers/42657205 | PubMed |
| 42625474 | Protective Effect of a Heat-Stabilized Bacteria Probiotic Preparation (VSL#3-HS) in a Mouse Model of Ulcerative Colitis Induced by Dextran Sulfate Sodium. | Mol Nutr Food Res | 2026 | https://conductscience.org/library/papers/42625474 | PubMed |
| 42458107 | Preventing Crohn's recurrence, Kono-S and extended mesenteric excision: network meta-analysis category. | Langenbecks Arch Surg | 2026 | https://conductscience.org/library/papers/42458107 | PubMed |
| 42450003 | Risk Factors and Predictive Biomarkers for Postoperative Complications in Crohn's Disease Surgery: Systematic Review. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42450003 | PubMed |
| 42445859 | Perianal Crohn Disease in a Patient With Congenital Afibrinogenemia: A Multidisciplinary Therapeutic Management Challenge. | Cureus | 2026 | https://conductscience.org/library/papers/42445859 | PubMed |
| 42410873 | Comparative Biophysical Analysis of Healthy and Inflamed Intestinal Membrane Models Using Langmuir Monolayers. | J Phys Chem B | 2026 | https://conductscience.org/library/papers/42410873 | PubMed |
| 42341067 | US commercial health plan use of corticosteroids in step therapy protocols: Frequency and clinical appropriateness. | J Manag Care Spec Pharm | 2026 | https://conductscience.org/library/papers/42341067 | PubMed |
| 42321339 | GLP-1 receptor agonists and clinical outcomes in adults with Crohn's disease and obesity: a propensity score-matched real-world cohort study. | Sci Rep | 2026 | https://conductscience.org/library/papers/42321339 | PubMed |
| 42257470 | Comparative efficacy of ustekinumab and vedolizumab in anti-TNF-naive and anti-TNF-exposed patients with Crohn's disease: a matched cohort study. | Proc (Bayl Univ Med Cent) | 2026 | https://conductscience.org/library/papers/42257470 | PubMed |
| 42221839 | Medication Use and Guideline Adherence in Inflammatory Bowel Disease Management: A Retrospective Study from a Tertiary Care Hospital in Pakistan (2019-2024). | Int J Gen Med | 2026 | https://conductscience.org/library/papers/42221839 | PubMed |
| 42221001 | Age-stratified management of pediatric perianal abscesses: a proposed framework integrating the "Developmental Healing Axis". | Front Pediatr | 2026 | https://conductscience.org/library/papers/42221001 | PubMed |
| 42220339 | Assessing data quality of inflammatory bowel disease patients in the All of Us research program. | JAMIA Open | 2026 | https://conductscience.org/library/papers/42220339 | PubMed |
| 42195202 | Benefits of Surgical Management in Ileocecal Crohn's Disease: A Review of the Past Decade (2020-2026). | Medicina (Kaunas) | 2026 | https://conductscience.org/library/papers/42195202 | PubMed |
| 42151576 | Efficacy and Safety of Risankizumab in Crohn's Disease: A Systematic Review and Meta-Analysis of Randomized Trials and Real-World Evidence. | Dig Dis Sci | 2026 | https://conductscience.org/library/papers/42151576 | PubMed |
| 42104284 | A gut vascular barrier damage-based scoring system predicts postoperative outcomes in Crohn's disease. | BMC Gastroenterol | 2026 | https://conductscience.org/library/papers/42104284 | PubMed |
| 42072281 | Inflammatory, Nutritional, and Atherogenic Profiles Associated with Histologic Activity in Inflammatory Bowel Disease. | Biomedicines | 2026 | https://conductscience.org/library/papers/42072281 | PubMed |
| 42065683 | Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trial. | Inflamm Bowel Dis | 2026 | https://conductscience.org/library/papers/42065683 | PubMed |
| 42016254 | Camel Milk as a Functional Food: Nutritional Composition, Health-Promoting Benefits, and Safety Considerations. | Food Sci Nutr | 2026 | https://conductscience.org/library/papers/42016254 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28601423
GET https://conductscience.org/api/papers/v1/28601423/cited_by?page=2